Document is current
Any future updates will be listed below
-
Authors
Oliver, Thomas R. W. https://orcid.org/0000-0003-4306-0102
Lawson, Andrew R. J. https://orcid.org/0000-0003-3592-1005
Lee-Six, Henry https://orcid.org/0000-0003-4831-8088
Tollit, Anna
Jung, Hyunchul
Hooks, Yvette
Sanghvi, Rashesh https://orcid.org/0000-0002-7703-9216
Young, Matthew D. https://orcid.org/0000-0003-0937-5290
Butler, Timothy M. https://orcid.org/0000-0001-5803-1035
Nicola, Pantelis A.
Treger, Taryn D.
Lensing, Stefanie V.
Burke, G. A. Amos https://orcid.org/0000-0003-2671-9972
Aquilina, Kristian
Löbel, Ulrike
Cortes-Ciriano, Isidro https://orcid.org/0000-0002-2036-494X
Hargrave, Darren
Jorgensen, Mette
Jessop, Flora A.
Coorens, Tim H. H. https://orcid.org/0000-0002-5826-3554
Flanagan, Adrienne M. https://orcid.org/0000-0002-2832-1303
Allinson, Kieren https://orcid.org/0000-0002-0779-7337
Martincorena, Inigo https://orcid.org/0000-0003-1122-4416
Jacques, Thomas S. https://orcid.org/0000-0002-7833-2158
Behjati, Sam https://orcid.org/0000-0002-6600-7665
- License Information
-
More Information
Article History
Received: 21 September 2023
Accepted: 22 January 2025
First Online: 25 February 2025
Competing interests
: I.M. is a cofounder and consultant of Quotient Therapeutics. D.H. provides consultancy to AstraZeneca/MedImmune, Alexion Pharmaceuticals, Bayer, Biodexa, Roche/Genentech and Novartis, as well as expert testimony to AstraZeneca and Novartis, and his expenses are covered by Alexion Pharmaceuticals, Boehringer Ingelheim, Roche/Genentech and Novartis. The other authors declare no competing interests.
